Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linda Mileshkin

Showing results (121-130 of 174) with videos related to

Pageof 18
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 8, 2022
Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site studyLisa Guccione, Krista Fisher, Linda Mileshkin, et al.
British Journal of Cancer|July 6, 2024
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancersRebecca Kristeleit, Alexandra Leary, Ana Oaknin, et al.
Journal of Geriatric Oncology|March 28, 2015
Geriatric assessment of older patients with cancer in Australia--a multicentre auditRoopa Lakhanpal, Jaclyn Yoong, Sachin Joshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2016
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT InhibitionGeorge Au-Yeung, Franziska Lang, Walid J Azar, et al.
Gynecologic Oncology|April 1, 2022
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 studyRonnie Shapira-Frommer, Linda Mileshkin, Ludmila Manzyuk, et al.
Oncoimmunology|March 28, 2017
Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i>-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibitionFlorine A Eggink, Inge C Van Gool, Alexandra Leary, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 9, 2016
Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancerInge C Van Gool, Ellen Stelloo, Remi A Nout, et al.
Gynecologic Oncology Reports|July 18, 2018
Advancing clinical research globally: Cervical cancer research network from MexicoBryan J Ager, Dolores Gallardo-Rincón, David Cantú de León, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2015
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiativeEllen Stelloo, Tjalling Bosse, Remi A Nout, et al.
Gynecologic Oncology|June 23, 2019
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMonica Tang, Rachel L O'Connell, Frederic Amant, et al.
Pageof 18

Showing results (121-130 of 174) with videos related to

Sort By:
Pageof 18
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 8, 2022
Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site studyLisa Guccione, Krista Fisher, Linda Mileshkin, et al.
British Journal of Cancer|July 6, 2024
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancersRebecca Kristeleit, Alexandra Leary, Ana Oaknin, et al.
Journal of Geriatric Oncology|March 28, 2015
Geriatric assessment of older patients with cancer in Australia--a multicentre auditRoopa Lakhanpal, Jaclyn Yoong, Sachin Joshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2016
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT InhibitionGeorge Au-Yeung, Franziska Lang, Walid J Azar, et al.
Gynecologic Oncology|April 1, 2022
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 studyRonnie Shapira-Frommer, Linda Mileshkin, Ludmila Manzyuk, et al.
Oncoimmunology|March 28, 2017
Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i>-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibitionFlorine A Eggink, Inge C Van Gool, Alexandra Leary, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 9, 2016
Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancerInge C Van Gool, Ellen Stelloo, Remi A Nout, et al.
Gynecologic Oncology Reports|July 18, 2018
Advancing clinical research globally: Cervical cancer research network from MexicoBryan J Ager, Dolores Gallardo-Rincón, David Cantú de León, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2015
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiativeEllen Stelloo, Tjalling Bosse, Remi A Nout, et al.
Gynecologic Oncology|June 23, 2019
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMonica Tang, Rachel L O'Connell, Frederic Amant, et al.
Pageof 18